Pseudoginsenoside F11 (Standard)

C[C@@]([C@@]12C)(C[C@H](O[C@@](O[C@H](CO)[C@@H](O)[C@@H]3O)([H])[C@@H]3O[C@@](O[C@@H](C)[C@H](O)[C@H]4O)([H])[C@@H]4O)[C@@]5([H])C6(C)C)[C@@](C[C@@H](O)[C@]1([H])[C@]([C@]7(O[C@@H](C(C)(O)C)CC7)C)([H])CC2)([H])[C@]5(CC[C@@H]6O)C

[1]Wang H, et al. The pseudoginsenoside F11 ameliorates cisplatin-induced nephrotoxicity without compromising its anti-tumor activity in vivo. Scientific Reports [2014, 4:4986]|[2]Li Zhu, et al. Pseudoginsenoside-F11 attenuates morphine-induced signalling in Chinese hamster ovary-μ cells. Neuroreport, 25 May 2001 - Volume 12 - Issue 7 - pp 1453-1456|[3]Yue Hao, et al. Pseudoginsenoside-F11 decreases morphine-induced behavioral sensitization and extracellular glutamate levels in the medial prefrontal cortex in mice. Pharmacology Biochemistry and Behavior
 Volume 86, Issue 4, April 2007, Pages 660–666